Individualized Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Haemophilia a Patients. Association Between Pharmacokinetic Parameters and Clinical Variables

MLA

Megías-Vericat, Juan Eduardo, et al. “Individualized Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Haemophilia a Patients. Association Between Pharmacokinetic Parameters and Clinical Variables.” Blood, vol. 128, no. 22, Dec. 2016, p. 3802. EBSCOhost, https://doi.org/10.1182/blood.V128.22.3802.3802.

APA

Megías-Vericat, J. E., Marqués, M. R., Haya, S., Cid, A. R., Querol, F., Monte, E., García-Dasí, M., Caunedo, P., Vila, C., Bosch, P., Curats, R., Sanz, M. Á., Poveda, J. L., & Bonanad, S. (2016). Individualized Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Haemophilia a Patients. Association Between Pharmacokinetic Parameters and Clinical Variables. Blood, 128(22), 3802. https://doi.org/10.1182/blood.V128.22.3802.3802

Chicago

Megías-Vericat, Juan Eduardo, María Remedios Marqués, Saturnino Haya, Ana Rosa Cid, Felipe Querol, Emilio Monte, María García-Dasí, et al. 2016. “Individualized Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Haemophilia a Patients. Association Between Pharmacokinetic Parameters and Clinical Variables.” Blood 128 (22): 3802. doi:10.1182/blood.V128.22.3802.3802.